These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35234549)

  • 1. Epidemiology and prevention of oesophageal adenocarcinoma.
    Ness-Jensen E
    Scand J Gastroenterol; 2022 Aug; 57(8):891-895. PubMed ID: 35234549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution and outcome of surveillance of Barrett's oesophagus over four decades in a UK District General Hospital.
    Royston C; Caygill C; Charlett A; Bardhan KD
    Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1365-1373. PubMed ID: 27571366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal trends of Barrett's oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study.
    Alexandropoulou K; van Vlymen J; Reid F; Poullis A; Kang JY
    Eur J Gastroenterol Hepatol; 2013 Jan; 25(1):15-21. PubMed ID: 23022985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis.
    Eusebi LH; Cirota GG; Zagari RM; Ford AC
    Gut; 2021 Mar; 70(3):456-463. PubMed ID: 32732370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis.
    Singh S; Garg SK; Singh PP; Iyer PG; El-Serag HB
    Gut; 2014 Aug; 63(8):1229-37. PubMed ID: 24221456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
    Tan MC; El-Serag HB; Yu X; Thrift AP
    Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adam, Eve and the reflux enigma: age and sex differences across the gastro-oesophageal reflux spectrum.
    Royston C; Bardhan KD
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):634-639. PubMed ID: 28151751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
    Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
    BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acid suppression and surgical therapy for Barrett's oesophagus.
    de Jonge PJ; Spaander MC; Bruno MJ; Kuipers EJ
    Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):139-50. PubMed ID: 25743462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barrett's oesophagus: optimal strategies for prevention and treatment.
    Fass R; Sampliner RE
    Drugs; 2003; 63(6):555-64. PubMed ID: 12656653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing Barrett's oesophagus.
    Hebbard GS; Nandurkar S
    Med J Aust; 2004 Apr; 180(8):375-6. PubMed ID: 15089724
    [No Abstract]   [Full Text] [Related]  

  • 12. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
    Dunbar KB; Souza RF; Spechler SJ
    Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barrett's oesophagus: Current controversies.
    Amadi C; Gatenby P
    World J Gastroenterol; 2017 Jul; 23(28):5051-5067. PubMed ID: 28811703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention in Barrett's oesophagus.
    Gordon V; Jankowski J
    Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):569-79. PubMed ID: 22122772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastroesophageal reflux disease. Are we acting in the best interest of our patients?
    Tebala GD
    Eur Rev Med Pharmacol Sci; 2016 Nov; 20(21):4553-4556. PubMed ID: 27874941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis.
    Desai TK; Krishnan K; Samala N; Singh J; Cluley J; Perla S; Howden CW
    Gut; 2012 Jul; 61(7):970-6. PubMed ID: 21997553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprevention in Barrett's oesophagus.
    Baruah A; Buttar NS
    Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):151-65. PubMed ID: 25743463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barrett's esophagus: A comprehensive review for the internist.
    Klavan H; Russell MB; Macklin J; Lee E; Aslanian HR; Muniraj T
    Dis Mon; 2018 Nov; 64(11):471-487. PubMed ID: 29880269
    [No Abstract]   [Full Text] [Related]  

  • 19. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients.
    Hvid-Jensen F; Pedersen L; Funch-Jensen P; Drewes AM
    Aliment Pharmacol Ther; 2014 May; 39(9):984-91. PubMed ID: 24617286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bile acids and Barrett's oesophagus: a sine qua non or coincidence?
    Sital RR; Kusters JG; De Rooij FW; Kuipers EJ; Siersema PD
    Scand J Gastroenterol Suppl; 2006; (243):11-7. PubMed ID: 16782617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.